» Articles » PMID: 26589973

Increasing Time Trends of Thin Melanomas in The Netherlands: What Are the Explanations of Recent Accelerations?

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2015 Nov 22
PMID 26589973
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A disproportional increase in in situ or thin melanomas may point at underlying causes such as increased melanoma awareness, as well as 'overdiagnosis' of melanoma in diagnostically equivocal small lesions.

Objectives: The purposes of this study were to estimate trends in melanoma incidence by sex, Breslow thickness (thin melanomas subdivided into four subgroups: <0.25 mm, 0.25-0.49 mm, 0.50-0.74 mm, and 0.75-1.0 mm), age and location, and to compare these with trends in subgroups of thicker melanomas.

Methods: Data on all histologically confirmed in situ and invasive melanomas diagnosed between 1994 and 2010 were retrieved from the Netherlands Cancer Registry. Trends in European standardised rates (ESRs) were assessed using joinpoint analysis, and expressed as estimated annual percentage change (EAPC).

Results: Between 1994 and 2010, 34,156 persons were diagnosed with an in situ or thin melanoma. The ESR of in situ melanomas doubled for males and females with a recent steeper rise in incidence (EAPC 12% (95% confidence interval [CI]: 8.1-16) and 13% (95% CI: 5.9-20), respectively). ESR for thin melanomas amongst males approximately doubled with a steep, but non-significant acceleration compared to other thickness categories since 2006 for <0.25 mm melanomas (EAPC 26% (95% CI: 2.1-35)). For female patients with thin melanomas the ESRs increased almost two-fold, except for <0.25 mm melanomas.

Conclusions: The incidence rates of in situ, thin and thick melanomas increased similarly between 1994 and 2010. Recently steep increases were found for in situ melanomas and thin melanomas in men. Explanations are 'overdiagnosis' in conjunction with increased ultraviolet exposure (natural and artificial) and therefore a 'true' increase, increased awareness, early detection, diagnostic drift and changed market forces in the Dutch health care system.

Citing Articles

The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand).

Win Myint T, Selak V, Elwood M Skin Health Dis. 2023; 3(2):e116.

PMID: 37013115 PMC: 10066759. DOI: 10.1002/ski2.116.


Patient presentation, skin biopsy utilization and cutaneous malignant melanoma incidence and mortality in northern Italy: Trends and correlations.

Bucchi L, Mancini S, Zamagni F, Crocetti E, Dal Maso L, Ferretti S J Eur Acad Dermatol Venereol. 2022; 37(2):293-302.

PMID: 36181283 PMC: 10092783. DOI: 10.1111/jdv.18635.


Clinical findings are not helpful in detecting lentigo maligna melanoma in patients with biopsy-proven lentigo maligna.

Zoutendijk J, Koljenovic S, Wakkee M, Mooyaart A, Nijsten T, van den Bos R J Eur Acad Dermatol Venereol. 2022; 36(12):2325-2330.

PMID: 35730990 PMC: 9796129. DOI: 10.1111/jdv.18346.


Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.

Garbe C, Keim U, Amaral T, Berking C, Eigentler T, Flatz L J Clin Oncol. 2022; 40(32):3741-3749.

PMID: 35709414 PMC: 9649277. DOI: 10.1200/JCO.22.00202.


The effect of screening on melanoma incidence and biopsy rates.

Whiteman D, Olsen C, Macgregor S, Law M, Thompson B, Dusingize J Br J Dermatol. 2022; 187(4):515-522.

PMID: 35531668 PMC: 9796145. DOI: 10.1111/bjd.21649.